Feasibility of biology-guided radiotherapy for metastatic renal cell carcinoma driven by PSMA PET imaging
- Author(s)
- Gaudreault, M; Chang, D; Hardcastle, N; McIntosh, L; Jackson, P; Kron, T; Udovicich, C; Hofman, MS; Siva, S;
- Journal Title
- Clinical and Translational Radiation Oncology
- Publication Type
- Research article
- Abstract
- BACKGROUND: Biology-guided radiotherapy (BgRT) is a novel treatment where the detection of positron emission originating from a volume called the biological tracking zone (BTZ) initiates dose delivery. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is a novel imaging technique that may improve patient selection for metastasis-directed therapy in renal cell carcinoma (RCC). This study aims to determine the feasibility of BgRT treatment for RCC. MATERIAL AND METHODS: All consecutive patients that underwent PSMA PET/CT scan for RCC staging at our institution between 2014 and 2020 were retrospectively considered for inclusion. GTVs were contoured on the CT component of the PET/CT scan. The tumor-to-background ratio was quantified from the normalized standardized uptake value (nSUV), defined as the ratio between SUVmax inside the GTV and SUVmean inside the margin expansion. Tumors were classified suitable for BgRT if (1) nSUV was greater or equal to an nSUV threshold and (2) if the BTZ was free of any PET-avid region other than the tumor. RESULTS: Out of this cohort of 83 patients, 47 had metastatic RCC and were included in this study. In total, 136 tumors were delineated, 1 to 22 tumors per patient, mostly in lung (40%). Using a margin expansion of 5 mm/10 mm/20 mm and nSUV threshold = 3, 66%/63%/41% of tumors were suitable for BgRT treatment. Uptake originating from another tumor, the kidney, or the liver was typically inside the BTZ in tumors judged unsuitable for BgRT. CONCLUSIONS: More than 60% of tumors were found to be suitable for BgRT in this cohort of patients with RCC. However, the proximity of PET-avid organs such as the liver or the kidney may affect BgRT delivery.
- Publisher
- Elsevier
- Department(s)
- Physical Sciences; Radiation Oncology
- PubMed ID
- 36942088
- Publisher's Version
- https://doi.org/10.1016/j.ctro.2023.100608
- Open Access at Publisher's Site
https://doi.org/10.1016/j.ctro.2023.100608- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-05-30 07:27:39
Last Modified: 2023-05-30 07:28:52